ASX:MYX Mayne Pharma Group (MYX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Mayne Pharma Group Stock (ASX:MYX) Get Mayne Pharma Group alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume5.47 million shsAverage VolumeN/AMarket CapitalizationA$446.85 millionP/E RatioN/ADividend Yield0.84%Price TargetN/AConsensus RatingN/A Company Overview Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. Read More Receive MYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mayne Pharma Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYX Stock News HeadlinesMayne Pharma Group Ltd. MYX (Australia: Sydney) - The Wall Street JournalAugust 22, 2025 | wsj.comHedge fund bets US suitor won’t get out of Mayne Pharma takeoverJuly 10, 2025 | afr.comWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume chip exports to China. That news sent their stocks flying. But here’s the truth: By the time the market reacts to big news, most traders are too late. | Timothy Sykes (Ad)Health Check: Whether stoic or simply too poor, Australians spurn GP visitsJune 4, 2025 | msn.comCosette terminates Mayne Pharma deal as legal challenge loomsJune 4, 2025 | afr.comMayne Pharma shares crash after suitor Cosette threatens to walkMay 21, 2025 | afr.comLunch Wrap: ASX marches on despite war jitters; Nufarm and Mayne plummetMay 20, 2025 | msn.comHealth Check: Mayne Pharma shares tumble after suitor threatens to walk over ‘adverse events’May 20, 2025 | msn.comSee More Headlines MYX Stock Analysis - Frequently Asked Questions How were Mayne Pharma Group's earnings last quarter? Mayne Pharma Group Limited (ASX:MYX) issued its earnings results on Friday, February, 22nd. The company reported $0.02 earnings per share for the quarter. Mayne Pharma Group had a negative net margin of 44.86% and a negative trailing twelve-month return on equity of 34.78%. What other stocks do shareholders of Mayne Pharma Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mayne Pharma Group investors own include Appen (APX), Aurora Cannabis (ACB), Sundance Energy (SNDE), Turquoise Hill Resources (TRQ), Pilbara Minerals (PILBF), Organigram Global (OGI) and Karoon Energy (KAR). Company Calendar Last Earnings2/22/2019Today10/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolASX:MYX CIKN/A Webwww.maynepharma.com Phone+61-8-82092666FaxN/AEmployees780Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth0.51Net Income-A$168.62 million Net Margins-44.86% Pretax MarginN/A Return on Equity-34.78% Return on Assets-2.33% Debt Debt-to-Equity Ratio8.55 Current Ratio1.47 Quick Ratio0.62 Sales & Book Value Annual SalesA$388.40 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.20 Book ValueA$5.59 per share Price / BookN/AMiscellaneous Outstanding Shares85,070,000Free FloatN/AMarket CapA$446.85 million OptionableNot Optionable Beta1.24 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (ASX:MYX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mayne Pharma Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mayne Pharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.